News Daily News New Roles for Anticoagulation Clinics in an Era of Non-Warfarin Options Todd Neale March 01, 2016
News Daily News Trial Affirms Aspirin Is Safe to Continue Before Coronary Artery Surgery Todd Neale February 25, 2016
News Daily News Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond December 23, 2015
News Daily News Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI Yael L. Maxwell December 22, 2015
News Industry News Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis December 16, 2015
News Daily News Many Lower-Income Patients Fail to Stick With Clopidogrel After PCI Todd Neale December 10, 2015
News Conference News AHA 2015 DAPT Score Provides ‘Personalized Medicine’ Tool for Determining Whether to Extend Therapy Beyond 1 Year Yael L. Maxwell November 09, 2015
News Conference News AHA 2015 SPRINT Makes Case for Even Lower BP Target in Many Hypertensive Patients Todd Neale November 08, 2015
News Industry News scPharmaceuticals Announces Positive Results from Pivotal Trial of its Novel Subcutaneous Furosemide Formulation in Patients with Heart Failure November 03, 2015
News Industry News Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure October 27, 2015
News Daily News More Discouraging News for DCBs in Treatment of Infrapopliteal Lesions L.A. McKeown October 26, 2015
News Industry News Mast Therapeutics Initiates Phase 2 Study Of Vepoloxamer For The Treatment Of Chronic Heart Failure October 26, 2015
News Conference News TCT 2015 Companies With Innovative Technologies Compete in TCT Shark Tank October 13, 2015
News Conference News TCT 2015 ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES Yael L. Maxwell October 12, 2015
News Industry News Extended Follow-Up Of ANTHEM-HF Patients Shows That Benefits Of Autonomic Regulation Therapy Are Maintained After 12 Months September 28, 2015
News Industry News Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial September 18, 2015
News Conference News ESC 2015 ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff September 09, 2015
News Conference News ESC 2015 NSAIDs Plus Anticoagulants a Bad Combination Caitlin E. Cox September 01, 2015
News Industry News Abbott Announces Positive Results Of Its Naturally Dissolving Stent From Absorb Japan Study September 01, 2015
News Conference News ESC 2015 TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics Yael L. Maxwell August 31, 2015